Jnana Therapeutics Presents New Positive Data from Phase 1/2 Study of JNT-517 in Individuals with Phenylketonuria – Results Support Planned Pivotal Study in Early 2025
September 04, 2024 07:30 ET
|
Jnana Therapeutics, Inc.
Jnana Therapeutics presents new positive data at SSIEM 2024 from Phase 1/2 study of JNT-517 in individuals with phenylketonuria (PKU).
Otsuka Pharmaceutical to Acquire Jnana Therapeutics Inc.
August 01, 2024 00:01 ET
|
Jnana Therapeutics, Inc.
Otsuka Pharmaceutical to acquire Jnana Therapeutics Inc.
Jnana Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
May 08, 2024 08:00 ET
|
Jnana Therapeutics, Inc.
Jnana CEO Joanne Kotz will present a corporate overview at the RBC Capital Markets Global Healthcare Conference on Tuesday, May 14, 2024 at 2:05 p.m. ET.
Jnana Therapeutics to Present at the RBC Capital Markets Healthcare Private Company Virtual Conference
December 06, 2023 08:00 ET
|
Jnana Therapeutics, Inc.
Jnana Therapeutics CEO Joanne Kotz will participate in a fireside chat on Dec. 13 at the RBC Capital Markets Healthcare Private Company Conference.
Jnana Therapeutics to Participate in Upcoming Investor Conferences
October 05, 2023 08:00 ET
|
Jnana Therapeutics, Inc.
BOSTON, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Jnana Therapeutics, a biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines for challenging-to-drug targets,...
Jnana Therapeutics to Participate in Upcoming Investor Conferences
September 06, 2023 08:00 ET
|
Jnana Therapeutics, Inc.
BOSTON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Jnana Therapeutics, a biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines for challenging-to-drug targets,...
Jnana Therapeutics Announces Milestone Achieved Under First Collaboration with Roche
May 24, 2023 07:00 ET
|
Jnana Therapeutics, Inc.
Achievement of research milestone for immune program triggers milestone payment BOSTON, May 24, 2023 (GLOBE NEWSWIRE) -- Jnana Therapeutics, a clinical-stage biotechnology company leveraging its...